Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 w
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year : 77%, 58
The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
11:00am, Saturday, 08'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between No
NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsu
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
11:14am, Friday, 07'th Feb 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options If you
LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
10:00am, Friday, 07'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:RE
Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman
09:43am, Friday, 07'th Feb 2025
SAN FRANCISCO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing legal
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Reg
March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN
05:45am, Friday, 07'th Feb 2025
NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit.
